Pentax Medical launches integrated endoscopy solutions platform

Pentax Medical has launched two dedicated electrosurgical and argon plasma coagulation (APC) platforms - the Endo arc and Endo Plus - to its therapeutic accessories range. The launch of these units strengthens Pentax Medical’s integrated endoscopy solutions offering, completing the pathway from screening to diagnostics and into therapeutics.

Researchers identify enzymes involved in colon cancer growth

University of Massachusetts Amherst food science researchers have pinpointed a set of enzymes involved in tumour growth that could be targeted to prevent or treat colon cancer. The study, ‘Targeted metabolomics identifies the cytochrome P450 monooxygenase eicosanoid pathway as a novel therapeutic target of colon tumorigenesis,’ was published in the journal Cancer Research.

Medicaid expansion increases CRC screening in Kentucky

A research team evaluating the impact of Medicaid expansion on the rates of colorectal cancer (CRC) screening, incidence, and survival in Kentucky’s low-income population, have found that the number of Medicaid patients who received screening after the expansion was more than triple the number of patients who were screened before the expansion. Additionally, CRC patients relying on Medicaid exhibited improved survival after the expansion compared to before it was implemented. The study.

Scientists demonstrate how high-fat diet drives colorectal cancer growth

A study led by Salk Institute scientists suggests that high-fat diets fuel colorectal cancer growth by upsetting the balance of bile acids in the intestine and triggering a hormonal signal that lets potentially cancerous cells thrive. The study, ‘FXR Regulates Intestinal Cancer Stem Cell Proliferation’, which appeared in Cell could explain why colorectal cancer, which can take decades to develop, is being seen in younger people growing up at a time when higher-fat diets are common.

Study shows annual non-invasive stool test effective for colon cancer screening

A study by Indiana University School of Medicine and the Regenstrief Institute provides the strongest evidence to date to support recommendations that average risk patients can safely opt for an annual, easy-to-use home stool test instead of a screening colonoscopy, according to the outcomes from a study published in the Annals of Internal Medicine.

Looking forward to Dublin 2019: An interview with ACPGBI President, Brendan Moran

In a series of interviews, we will be previewing this year’s ACPGBI annual meeting in Dublin, 1-3 July. We talked to Mr Brendan Moran, President of the ACPGBI, who highlighted some of the key sessions, presentations and speakers, as well as encouraging those with an interest in coloproctology to attend the meeting.

Colorectal cancer cells killed by assassin antibody

A team of researchers at University of Saskatchewan (Uask) led by Dr Humphrey Fonge, an assistant professor in the College of Medicine's medical imaging department, has created an assassin antibody with attached radioactive molecules which cling to colorectal cancer cells and destroy them. The assassin antibody kills the colorectal cancer cell by releasing high energy to the DNA of the cell. Current antibody drug therapies can slow down the spread of colorectal cancer, but do not destroy the existing cancer cells.

Position statement examines role of interventional inflammatory bowel disease in the era of biologic therapy

According to a new statement from a panel of national and international experts in gastroenterology, inflammatory bowel disease (IBD) and other areas, interventional (or therapeutic) IBD endoscopy has an expanding role in the treatment of disease and of adverse events from surgery.